2026 ACC Guideline Changes on Aspirin for Primary Prevention
There are no 2026 ACC guideline changes specifically addressing aspirin for primary prevention—the most recent comprehensive guidance remains the 2019 ACC/AHA Primary Prevention Guidelines, which recommend against routine aspirin initiation in adults over 70 years for primary prevention (Class III: Harm). 1
Key Recommendations for Patients Over 70 Years
Without Established ASCVD (Primary Prevention)
Aspirin should NOT be routinely initiated in adults over 70 years for primary prevention. 1 The 2019 ACC/AHA guidelines explicitly state that prophylactic aspirin in this age group is "potentially harmful" due to significantly elevated bleeding risk that outweighs any cardiovascular benefit. 1
- Bleeding risk increases substantially with age, particularly after 60-70 years 2
- Recent extended follow-up data from the ASPREE trial (2025) reinforces this recommendation, showing no long-term MACE benefit and increased major hemorrhage risk (HR 1.24) in older adults taking aspirin 3
- The USPSTF (2022) similarly recommends against initiating aspirin in adults ≥60 years (Grade D recommendation) 4
Important caveat: While routine use is not recommended, the guidelines acknowledge "insufficient evidence to comment on whether there may be select circumstances" where aspirin might be discussed with adults >70 years in the context of other high-risk factors (e.g., strong family history of premature MI, inability to achieve risk factor targets, significantly elevated coronary artery calcium). 1 However, this remains a narrow exception requiring careful bleeding risk assessment.
With Established ASCVD (Secondary Prevention)
Aspirin IS recommended for secondary prevention in patients with established ASCVD, regardless of age. 5 This is a fundamentally different indication than primary prevention—the benefit-to-risk ratio strongly favors aspirin use when cardiovascular disease is already present.
For Patients 40-70 Years (Primary Prevention Context)
The 2019 guidelines provide a Class IIb recommendation (may be considered) for aspirin in adults 40-70 years who:
- Have ≥10% 10-year ASCVD risk
- Are at low bleeding risk
- Cannot achieve optimal control of other modifiable risk factors 1
This represents a significant narrowing from previous recommendations, emphasizing that aspirin should be reserved for select higher-risk individuals rather than routine use.
Critical Bleeding Risk Factors to Assess
Avoid aspirin in patients with: 1
- History of gastrointestinal bleeding or peptic ulcer disease
- Age >70 years (for primary prevention)
- Thrombocytopenia or coagulopathy
- Chronic kidney disease
- Concurrent use of NSAIDs, steroids, anticoagulants (warfarin, DOACs)
Common Pitfalls
Confusing primary and secondary prevention: Many patients >70 years inappropriately receive aspirin for primary prevention—one registry study found 27.6% of patients were receiving aspirin inappropriately 5
Continuing aspirin initiated years ago: Patients who started aspirin under older guidelines should be reassessed for bleeding risk and whether they truly have established ASCVD
Dose considerations: If aspirin is indicated, use low-dose (81 mg) only—higher doses increase bleeding without additional cardiovascular benefit 1
Note on 2026 Dyslipidemia Guidelines
The 2026 ACC/AHA Dyslipidemia Guidelines 6 focus on cholesterol management and do not modify the 2019 aspirin recommendations for primary prevention. Aspirin guidance remains governed by the 2019 Primary Prevention Guidelines.